Navigation Links
Questcor Reports Third Quarter Financial Results
Date:10/29/2013

nical studies. Questcor is funding research and development, both in-house and through independent physician sponsored studies, for the following:

Label Enhancement Programs:

  • Acute Respiratory Distress Syndrome (ARDS): The Company announced on October 22, 2013 that it will commence a Phase 2 study to explore the efficacy and safety of Acthar in patients with ARDS. ARDS is an acute life threatening lung condition that can result from pulmonary and non-pulmonary infections or a multitude of other serious conditions.
  • Amyotrophic Lateral Sclerosis (ALS): Patient recruitment continues at thirteen U.S. clinical sites in a company-sponsored dose-ranging Phase 2 clinical trial to evaluate the safety and tolerability of Acthar in patients with ALS, often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Research Regarding Approved Indications:

  • Idiopathic Membranous Nephropathy: Enrollment continues in a company-sponsored Phase 4 trial in idiopathic membranous nephropathy. Patients enrolled in this study are refractory, or non-responsive, to current standard therapies or have relapsed after partial remission on current standard therapies.
  • Lupus: Enrollment continues in a company-sponsored multi-site Phase 4 company-sponsored clinical trial to evaluate the efficacy and safety of daily Acthar administration over a 6-month period in patients with persistently active lupus.
  • Planning activities related to the initial evaluation of a select grouping of potential Synacthen indications are in progress.  Questcor will provide further updates on this development
    '/>"/>

    SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    2. Questcor to Report Second Quarter Results on July 24, 2012
    3. Questcor Reports Second Quarter Financial Results
    4. Questcor Pharmaceuticals to Present at Investor Conferences in September
    5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    6. Questcor Comments on Insurance Policy Bulletin
    7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
    (Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
    (Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
    Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
    ... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
    ... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
    Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
    (Date:7/14/2014)... The Encino cosmetic dentist ... Lumineers and porcelain veneers. These restorations are an ... preparation and greater loss of healthy tooth tissue. They ... visible flaws on the tooth. Encino dentist Dr. Mastour ... to ensure they offer the most appropriate treatment recommendations ...
    (Date:7/14/2014)... 14, 2014 (HealthDay News) -- Being physically active in ... Alzheimer,s disease and other types of dementia, suggest the ... we found that physical exercise at various levels, especially ... Geda from the Mayo Clinic, said in an Alzheimer,s ... they are not yet conclusive. More research is needed ...
    (Date:7/14/2014)... July 14, 2014 ... performance liquid chromatography or UPLC is a ... liquid chromatography that involves the use of ... to separate chromatographic compounds. This highly sensitive ... detection and analysis of chromatography samples. UPLC ...
    (Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
    (Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
    Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Staying Active May Help Prevent Dementia 2Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3
    ... Speakers ... Exposition (ACE10), June 20-24, in Chicago, Illinois. , ... Denver (Vocus) February 25, 2010 -- Speakers have been ... June 20-24, in Chicago, Illinois. , ,Denis Hayes will be the highlighted speaker at ...
    ... , ... Examines IT Executive,s Opinions on Outsourcing , ... Westborough, MA (PRWEB) February 25, 2010 -- Advans, a ... that highlight the growing popularity of domestic outsourcing. According to the Advans’ IT Outsourcing ...
    ... ... New Inguinal Hernia Product Range Freedom-I, with an Aim to Improve Surgical Outcomes and Take ... ... focused on bringing innovations to the field of medical devices. For the past four years ...
    ... ... for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a ... of OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for ...
    ... ... feel like they are falling apart at home, psychotherapeutic interventions provide families with a growing ... (PRWEB) ... like they are falling apart at home, psychotherapeutic interventions provide families with a growing array ...
    ... ... continue to await their orders of Xyngular Xyng™ as Zija,s NEW! ... Xyngular™ to market months before their NEW! Xyng™ product was released ... People from all over the world are calling to become distributors ...
    Cached Medicine News:Health News:AWWA Announces ACE10 Speakers 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: